Capsida Biotherapeutics yesterday revealed US pharma major AbbVie has exercised an option for the first neurodegenerative ...

Gene therapy firm Capsida Biotherapeutics is advancing the first of its AbbVie-partnered neurodegenerative disease therapies ...

Cents, the largest leading all-in-one business management platform powering the way garment care SMBs grow, manage, and understand their businesses, today announced the launch of Cents Assist, an ...

QurAlis Corporation ("QurAlis"), a clinical-stage biotechnology company driving scientific breakthroughs into powerful precision medicines that have the potential to alter the trajectory of ...

Capsida Biotherapeutics ("Capsida") today announced that AbbVie has exercised an option for the first neurodegenerative ...

AbbVie Inc. (NYSE:ABBV – Get Free Report) crossed below its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $183.76 and traded as low as $177.29.

Shares of AbbVie Inc. ABBV slid 0.44% to $179.20 Thursday, on what proved to be an all-around mixed trading session for the stock market, with the Dow Jones Industrial Average DJIA rising 0.07% to ...

With its shares offering a total return of nearly 49% over the last three years, trumping the market's return of 33%, AbbVie (NYSE: ABBV) is a powerhouse big pharma that has a lot of upside to ...

This discount is shown at checkout, if applicable. AbbVie is slated to buy oral peptide developer Nimble Therapeutics for $200 million, with the potential for a milestone payment. Nimble was spun ...

In addition to its wholly owned programs, the Company has validating partnerships with AbbVie, Lilly, and CRISPR Therapeutics. Capsida was founded in 2019 by lead investors Versant Ventures and ...

On December 18, a recent SEC filing unveiled that Kevin K Buckbee, SVP at AbbVie ABBV made an insider sell. What Happened: A Form 4 filing from the U.S. Securities and Exchange Commission on ...